KORU Medical Q2 returns to profit on lower manufacturing costs and higher average selling prices

Koru Medical Systems

05/08/2026 21:50

Overview
U.S. infusion device maker's Q2 revenue rose 18% yr/yr to $12 mln
Q2 net income improved to $0.25 mln from a loss last year
Company acquired connected monitoring technology asset to enhance platform

Outlook
KORU Medical narrows 2026 revenue guidance to $47.5-$48.5 mln
Company raises 2026 gross margin outlook to 62%-64%
KORU Medical expects international core growth to moderate due to European market launch dynamics

Result Drivers
CORE REVENUE GROWTH - Domestic and international core revenues rose on higher pump and consumable volumes, driven by new patient starts and distributor purchases for pre-filled syringe conversions
GROSS MARGIN IMPROVEMENT - Gross margin increased due to lower manufacturing costs and higher average selling prices
PHARMA SERVICES DECLINE - Pharma services and clinical trials revenue fell due to lower clinical trial product revenues related to customer order timing

Company press release: ID:nBw7r59Dqa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
 
$252,449
 
Q2 Gross Margin
 
65.10%
 
Q2 Operating Expenses
 
$7.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for KORU Medical Systems Inc is $7.00, about 65.1% above its August 4 closing price of $4.24

Reuters Recommended Reads
Aug 5 - Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal
Aug 3 - Viemed Healthcare Q2 revenue rises on ventilator patient growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)